[Factor AF2--the 4th column in tumor therapy. Documentation No.22].
Factor AF2 is an extract from the spleen and liver of sheep embryos and lambs. The product contains biotechnologically produced, chromatographically uniform, molecularly standardized polypeptides, glycopeptides, glycolipids and nucleotides, deproteinized and free of pyrogens'. Factor AF2 is intended mainly for use in 'supportive antitumour therapy', as a 'biological antiemetic and analgesic'. The proposed duration of treatment is usually more than six months. The dosage varies considerably according to the indication. The average daily costs are, therefore, between DM 4.- (prevention of recurrence) and DM 107.- (adjuvant to chemotherapy). Allergic reactions have been reported in 'rare cases'. Factor AF2 was developed in the forties by Guarnieri in Rome. Since 1984, Factor AF2 is 'biotechnologically' produced and as a 'biological response modifier' (BRM) in the oncotherapy distributed by Biosyn Arzneimittel GmbH, Stuttgart. Dr. rer. nat. T. Stiefel and Dr. rer. nat. H. Porcher are the representatives of Biosyn Arzneimittel GmbH. In the past, both worked with Vitorgan Arzneimittel GmbH (cytoplasmatic therapy according to Theurer). It is claimed that Factor AF2 contains 'immunomodulating and immunorestorative biomolecules' assignable to the BRM group. Terms and investigations from current immunological research are applied to Factor AF2. No preclinical investigations are available which demonstrate any cytostatic effect of Factor AF2. In vivo, no effects were observed on the transplanted meth-A-sarcoma in mice.(ABSTRACT TRUNCATED AT 250 WORDS)
Kast
A
A
Schweizerische Krebsliga, Schweizerische Gesellschaft für Onkologie, Bern.
Hauser
S P
SP
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004622:Embryo, Mammalian; D006801:Humans; D008099:Liver; D012756:Sheep; D013154:Spleen; D014020:Tissue Extracts / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D014020:Tissue Extracts; C064467:factor AF2
Factor AF2--die vierte Säule in der Tumortherapie. Dokumentation Nr. 22.